A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European Journal of Human Genetics

• Publication date

  2018-12-20

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/s41431-018-0323-zPMID 30573803PMCID PMC6460636
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phenotype expansion and development in Kosaki overgrowth syndrome

  2018cited by this paper
• PDGFRB gain‐of‐function mutations in sporadic infantile myofibromatosis

  2017cited by this paper
• STAT1 modulates tissue wasting or overgrowth downstream from PDGFRβ

  2017cited by this paper
• Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases

  2017cited by this paper
• Expansion of the phenotype of Kosaki overgrowth syndrome

  2017cited by this paper
• A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib

  2017cited by this paper
• Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene

  2017cited by this paper
• PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib

  2016cited by this paper
• A Point Mutation in PDGFRB Causes Autosomal-Dominant Penttinen Syndrome.

  2015cited by this paper
• Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB mutation.

  2015cited by this paper
• SHP2 sails from physiology to pathology.

  2015cited by this paper
• Targeting the PDGF Signaling Pathway in the Treatment of Non-Malignant Diseases

  2014cited by this paper
• Idiopathic basal ganglia calcification-associated PDGFRB mutations impair the receptor signalling

  2014cited by this paper
• Growth deceleration in children treated with imatinib for chronic myeloid leukaemia.

  2014cited by this paper
• Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification

  2013cited by this paper
• Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis.

  2013cited by this paper
• Antagonism between binding site affinity and conformational dynamics tunes alternative cis-interactions within Shp2

  2013cited by this paper
• Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up

  2013cited by this paper
• Platelet-derived growth factors and their receptors: structural and functional perspectives.

  2013cited by this paper
• A recurrent PDGFRB mutation causes familial infantile myofibromatosis.

  2013cited by this paper
• Acro‐osteolysis, keloid like‐lesions, distinctive facial features, and overgrowth: Two newly recognized patients with premature aging syndrome, penttinen type

  2013cited by this paper
• Role of platelet-derived growth factors in physiology and medicine.

  2008cited by this paper
• A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.

  2007cited by this paper
• Tyrosyl Phosphorylation of Shp2 Is Required for Normal ERK Activation in Response to Some, but Not All, Growth Factors*

  2003cited by this paper
• Receptor-Specific Regulation of Phosphatidylinositol 3′-Kinase Activation by the Protein Tyrosine Phosphatase Shp2

  2002cited by this paper
• Apoptosis of mortal human fibroblasts transformed by the bovine papillomavirus E5 oncoprotein.

  2002cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• Transformation of mortal human fibroblasts and activation of a growth inhibitory pathway by the bovine papillomavirus E5 oncoprotein.

  2000cited by this paper
• Rapid Production of Retroviruses for Efficient Gene Delivery to Mammalian Cells Using 293T Cell–Based Systems

  1999cited by this paper
• New progeroid disorder.

  1997cited by this paper
• Production of high-titer helper-free retroviruses by transient transfection.

  1993cited by this paper

• On subcellular distribution of the zinc finger 469 protein (ZNF469) and observed discrepancy in the localization of endogenous and overexpressed ZNF469

  2025cites this paper
• Recurrent platelet-derived growth factor receptor beta gene mutations in Kosaki overgrowth syndrome: a molecular and clinical overview.

  2025cites this paper
• Molecular basis of variations in facial soft tissues: insights from cichlid fishes.

  2025cites this paper
• Variable response of germline activating PDGFRB variants to receptor tyrosine kinase inhibitors: implications for treatment

  2025cites this paper
• Treatment of PDGFRB ‐Related Penttinen Syndrome With Imatinib in a Young Child

  2025cites this paper
• ‘Knowing and Treating Kosaki/Penttinen syndrome’ international collaborative consortium: recommendations for follow-up, natural history and a real-life observational study about safety and efficacy profile of tyrosine kinase inhibitors

  2025cites this paper
• Temperature as a Key Modulator: Investigating Phosphorylation Patterns of p.Asn666 PDGFRB Variants and Their Role in Downstream Signaling

  2025influential citation
• A Case of Penttinen Syndrome With Radiographic Acroosteolysis From Age 3 Years

  2025cites this paper
• Management of Pediatric Patient with Multiple Cranial, Intracranial, and Spinal Manifestations of Penttinen Syndrome: A Case Report

  2024cites this paper
• Unicentric Castleman Disease: Updates and Novel Insights Into Spindle Cell Proliferations and Aggressive Forms of a Localized Disease

  2024cites this paper
• Defining the progeria phenome

  2024cites this paper
• Corneal Vascularization Associated With a Novel PDGFRB Variant

  2023cites this paper
• A Pellino‐2 variant is associated with constitutive NLRP3 inflammasome activation in a family with ocular pterygium–digital keloid dysplasia

  2023cites this paper
• Penttinen syndrome‐associated PDGFRB Val665Ala variant causes aberrant constitutive STAT1 signalling

  2022cites this paper
• Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy

  2022influential citation
• Lipodystrophy-associated progeroid syndromes

  2022cites this paper
• PDGF receptor mutations in human diseases

  2021cites this paper
• Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome

  2021cites this paper
• First case report of Penttinen syndrome from India

  2021cites this paper
• Skeletal stem cell fate defects caused by Pdgfrb activating mutation.

  2021cites this paper
• Pellino‐2 in nonimmune cells: novel interaction partners and intracellular localization

  2021cites this paper
• Positive response to imatinib in PDGFRB‐related Kosaki overgrowth syndrome

  2021cites this paper
• A small molecule inhibitor targeting SHP2 mutations for the lung carcinoma

  2021cites this paper
• An activating mutation in Pdgfrb causes skeletal stem cell defects with osteopenia and overgrowth in mice

  2021cites this paper
• Temperature-dependent autoactivation associated with clinical variability of PDGFRB Asn666 substitutions

  2021cites this paper
• Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy

  2020cites this paper
• Premature aging disorders: A clinical and genetic compendium

  2020cites this paper
• Kosaki overgrowth syndrome: A novel pathogenic variant in PDGFRB and expansion of the phenotype including cerebrovascular complications

  2020cites this paper
• Kosaki overgrowth syndrome: A newly identified entity caused by pathogenic variants in platelet‐derived growth factor receptor‐beta

  2019cites this paper
• Molecular mechanisms underlying nuchal hump formation in dolphin cichlid, Cyrtocara moorii

  2019cites this paper